EGFR and neoplasm: This reduction in EGFR expression could elucidate the mechanism behind the observed decrease in tumor aggressiveness and increased afatinib sensitivity, highlighting the therapeutic potential of inhibiting PSMC1 and PSMD11 in LUAD.